Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation

Clinical Science

Volumn 126, Issue 10, 2014, Pages 707-720

  Zhou, Guangyu ^a,b   Cheung, Alfred K ^b,c   Liu, Xia ^b   Huang, Yufeng ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Albuminuria; Angiotensin II; Diabetic nephropathy; Inflammation; NADPH oxidase (Nox); Podocyte

Indexed keywords

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; EXTRACELLULAR MATRIX PROTEINS; FIBRONECTINS; GENE EXPRESSION REGULATION; INFLAMMATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; KIDNEY CORTEX; KIDNEY GLOMERULUS; MEMBRANE PROTEINS; MICE; OXIDATIVE STRESS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PODOCYTES; RNA, MESSENGER; TETRAZOLES; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME; VALINE; WT1 PROTEINS;

EID: 84893958447     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20130223     Document Type: Article

References (44)

1. Gerstein, H. C., Mann, J. F., Yi, Q., Zinman, B., Dinneen, S. F., Hoogwerf, B., Halle, J. P., Young, J., Rashkow, A., Joyce, C. et al. (2001) Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286, 421-426
2. de Zeeuw, D., Remuzzi, G., Parving, H. H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E. and Brenner, B. M. (2004) Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 65, 2309-2320
3. Palmer, B. F. (2007) Proteinuria as a therapeutic target in patients with chronic kidney disease. Am. J. Nephrol. 27, 287-293
4. Hou, F. F., Xie, D., Zhang, X., Chen, P. Y., Zhang, W. R., Liang, M., Guo, Z. J. and Jiang, J. P. (2007) Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J. Am. Soc. Nephrol. 18, 1889-1898
5. Palmer, B. F. (2008) Supratherapeutic doses of angiotensin receptor blockers to decrease proteinuria in patients with chronic kidney disease. Am. J. Nephrol. 28, 381-390
6. Drueke, T. B., Locatelli, F., Clyne, N., Eckardt, K. U., Macdougall, I. C., Tsakiris, D., Burger, H. U. and Scherhag, A. (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 355, 2071-2084
7. Hollenberg, N. K., Parving, H. H., Viberti, G., Remuzzi, G., Ritter, S., Zelenkofske, S., Kandra, A., Daley, W. L. and Rocha, R. (2007) Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J. Hypertens. 25, 1921-1926
8. Gu, C., Zhou, G., Noble, N. A., Border, W. A., Cheung, A. K. and Huang, Y. (2012) Targeting reduction of proteinuria in glomerulonephritis: maximizing the antifibrotic effect of valsartan by protecting podocytes. J. Renin Angiotensin Aldosterone Syst., doi:10.1177/1470320312466127
9. Sharma, K., McCue, P. and Dunn, S. R. (2003) Diabetic kidney disease in the db/db mouse. Am. J. Physiol. Renal Physiol. 284, F1138-F1144
10. Huang, Y., Border, W. A., Yu, L., Zhang, J., Lawrence, D. A. and Noble, N. A. (2008) A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. J. Am. Soc. Nephrol. 19, 329-338
11. Rennard, S. I., Berg, R., Martin, G. R., Foidart, J. M. and Robey, P. G. (1980) Enzyme-linked immunoassay (ELISA) for connective tissue components. Anal. Biochem. 104, 205-214
12. Yu, L., Border, W. A., Anderson, I., McCourt, M., Huang, Y. and Noble, N. A. (2004) Combining TGF-β inhibition and Angiotensin II blockade results in enhanced anti-fibrotic effect. Kidney Int. 66, 1774-1784
13. Shankland, S. J. (2006) The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int. 69, 2131-2147
14. Ziyadeh, F. N. and Wolf, G. (2008) Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr. Diabetes Rev. 4, 39-45
15. Yu, D., Petermann, A., Kunter, U., Rong, S., Shankland, S. J. and Floege, J. (2005) Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J. Am. Soc. Nephrol. 16, 1733-1741
16. Sanden, S. K., Wiggins, J. E., Goyal, M., Riggs, L. K. and Wiggins, R. C. (2003) Evaluation of a thick and thin section method for estimation of podocyte number, glomerular volume, and glomerular volume per podocyte in rat kidney with Wilms' tumor-1 protein used as a podocyte nuclear marker. J. Am. Soc. Nephrol. 14, 2484-2493
17. Guo, J. K., Menke, A. L., Gubler, M. C., Clarke, A. R., Harrison, D., Hammes, A., Hastie, N. D. and Schedl, A. (2002) WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis. Hum. Mol. Genet. 11, 651-659
18. Wada, J. and Makino, H. (2013) Inflammation and the pathogenesis of diabetic nephropathy. Clin. Sci. 124, 139-152
19. Tojo, A., Asaba, K. and Onozato, M. L. (2007) Suppressing renal NADPH oxidase to treat diabetic nephropathy. Expert Opin. Ther. Targets 11, 1011-1018
20. Xu, M., Dai, D. Z. and Dai, Y. (2009) Normalizing NADPH oxidase contributes to attenuating diabetic nephropathy by the dual endothelin receptor antagonist CPU0213 in rats. Am. J. Nephrol. 29, 252-256
21. Sedeek, M., Gutsol, A., Montezano, A. C., Burger, D., Nguyen Dinh Cat, A., Kennedy, C. R., Burns, K. D., Cooper, M. E., Jandeleit-Dahm, K., Page, P. et al. (2013) Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes. Clin. Sci. 124, 191-202
22. Villa, L., Boor, P., Konieczny, A., Kunter, U., van Roeyen, C. R., Denecke, B., Gan, L., Kupper, M. B., Hoffmann, K., Eitner, F. et al. (2011) Effects and mechanisms of angiotensin II receptor blockade with telmisartan in a normotensive model of mesangioproliferative nephritis. Nephrol. Dial. Transplant. 26, 3131-3143
23. Yadav, A., Vallabu, S., Arora, S., Tandon, P., Slahan, D., Teichberg, S. and Singhal, P. C. (2010) ANG II promotes autophagy in podocytes. Am. J. Physiol. Cell Physiol. 299, C488-C496
24. Ren, Z., Liang, W., Chen, C., Yang, H., Singhal, P. C. and Ding, G. (2012) Angiotensin II induces nephrin dephosphorylation and podocyte injury: role of caveolin-1. Cell. Signal. 24, 443-450
25. Hsu, H. H., Hoffmann, S., Endlich, N., Velic, A., Schwab, A., Weide, T., Schlatter, E. and Pavenstadt, H. (2008) Mechanisms of angiotensin II signaling on cytoskeleton of podocytes. J. Mol. Med. 86, 1379-1394
26. Fukuda, A., Wickman, L. T., Venkatareddy, M. P., Sato, Y., Chowdhury, M. A., Wang, S. Q., Shedden, K. A., Dysko, R. C., Wiggins, J. E. and Wiggins, R. C. (2012) Angiotensin II-dependent persistent podocyte loss from destabilized glomeruli causes progression of end stage kidney disease. Kidney Int. 81, 40-55
27. Navarro, J. F., Mora, C., Muros, M. and Garcia, J. (2006) Urinary tumour necrosis factor-α excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. Nephrol. Dial. Transplant. 21, 3428-3434
28. Pavlatou, M. G., Mastorakos, G., Margeli, A., Kouskouni, E., Tentolouris, N., Katsilambros, N., Chrousos, G. P. and Papassotiriou, I. (2011) Angiotensin blockade in diabetic patients decreases insulin resistance-associated low-grade inflammation. Eur. J. Clin. Invest. 41, 652-658
29. Chipitsyna, G., Gong, Q., Gray, C. F., Haroon, Y., Kamer, E. and Arafat, H. A. (2007) Induction of monocyte chemoattractant protein-1 expression by angiotensin II in the pancreatic islets and β-cells. Endocrinology 148, 2198-2208
30. Tashiro, K., Koyanagi, I., Saitoh, A., Shimizu, A., Shike, T., Ishiguro, C., Koizumi, M., Funabiki, K., Horikoshi, S., Shirato, I. and Tomino, Y. (2002) Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy. J. Clin. Lab. Anal. 16, 1-4
31. Dandona, P., Kumar, V., Aljada, A., Ghanim, H., Syed, T., Hofmayer, D., Mohanty, P., Tripathy, D. and Garg, R. (2003) Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-κB, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J. Clin. Endocrinol. Metab. 88, 4496-4501
32. Shishido, T., Konta, T., Nishiyama, S., Miyashita, T., Miyamoto, T., Takasaki, S., Nitobe, J., Watanabe, T., Takeishi, Y. and Kubota, I. (2011) Suppressive effects of valsartan on microalbuminuria and CRP in patients with metabolic syndrome (Val-Mets). Clin. Exp. Hypertens. 33, 117-123
33. Forbes, J. M., Coughlan, M. T. and Cooper, M. E. (2008) Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57, 1446-1454
34. Kim, Y. K., Lee, M. S., Son, S. M., Kim, I. J., Lee, W. S., Rhim, B. Y., Hong, K. W. and Kim, C. D. (2002) Vascular NADH oxidase is involved in impaired endothelium-dependent vasodilation in OLETF rats, a model of type 2 diabetes. Diabetes 51, 522-527
35. Sonta, T., Inoguchi, T., Tsubouchi, H., Sekiguchi, N., Kobayashi, K., Matsumoto, S., Utsumi, H. and Nawata, H. (2004) Evidence for contribution of vascular NAD(P)H oxidase to increased oxidative stress in animal models of diabetes and obesity. Free Radic. Biol. Med. 37, 115-123
36. Bedard, K. and Krause, K. H. (2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 87, 245-313
37. Fu, Y., Zhang, R., Lu, D., Liu, H., Chandrashekar, K., Juncos, L. A. and Liu, R. (2010) NOX2 is the primary source of angiotensin II-induced superoxide in the macula densa. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298, R707-R712
38. Murdoch, C. E., Alom-Ruiz, S. P., Wang, M., Zhang, M., Walker, S., Yu, B., Brewer, A. and Shah, A. M. (2011) Role of endothelial Nox2 NADPH oxidase in angiotensin II-induced hypertension and vasomotor dysfunction. Basic Res. Cardiol. 106, 527-538
39. Gorin, Y., Ricono, J. M., Kim, N. H., Bhandari, B., Choudhury, G. G. and Abboud, H. E. (2003) Nox4 mediates angiotensin II-induced activation of Akt/protein kinase B in mesangial cells. Am. J. Physiol. Renal Physiol. 285, F219-F229
40. Schroder, K., Zhang, M., Benkhoff, S., Mieth, A., Pliquett, R., Kosowski, J., Kruse, C., Luedike, P., Michaelis, U. R., Weissmann, N. et al. (2012) Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ. Res. 110, 1217-1225
41. Bakris, G. L. and Weir, M. R. (2008) Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression. Postgrad. Med. 120, 33-42
42. Wang, P., Tang, F., Li, R., Zhang, H., Chen, S., Liu, P. and Huang, H. (2007) Contribution of different Nox homologues to cardiac remodeling in two-kidney two-clip renovascular hypertensive rats: effect of valsartan. Pharmacol. Res. 55, 408-417
43. Nakayama, M., Inoguchi, T., Sonta, T., Maeda, Y., Sasaki, S., Sawada, F., Tsubouchi, H., Sonoda, N., Kobayashi, K., Sumimoto, H. and Nawata, H. (2005) Increased expression of NAD(P)H oxidase in islets of animal models of Type 2 diabetes and its improvement by an AT1 receptor antagonist. Biochem. Biophys. Res. Commun. 332, 927-933
44. Wei, Y., Sowers, J. R., Clark, S. E., Li, W., Ferrario, C. M. and Stump, C. S. (2008) Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-κB activation via NADPH oxidase. Am. J. Physiol. Endocrinol. Metab. 294, E345-E351